Artículos del autor

solaci

Femoropopliteal

IVUS in Femoropopliteal PCI: Should We Start Using It?

For approximately two decades now, PCI has been the treatment of choice in femoropopliteal territory, and even...
solaci -
Bifurcations

Wire Jailing at Side Branch to Prevent Occlusion After Main Vessel Stenting: Should It Be the Standard of Care?

While the ideal treatment for coronary bifurcation is provisional stenting, this can be associated with side branch...
solaci -
Other

TRICENTO: Promising Results for Severe Tricuspid Valve Regurgitation

Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical...
solaci -
Acute coronary syndromes

REVERSE-IT | Bentracimab: Progress on the Antidote for Ticagrelor in Emergency Scenarios

Optimizing an antiplatelet therapy after an acute coronary syndrome (ACS) aims at reducing the major adverse cardiac...
solaci -
Institutional News

Dr. Marco Valgimigli Presented the Outcomes of MASTER-DAPT in a New SOLACI Webinar

Re-watch our webinar on “New Evidence in the Treatment of HBR Patients: Balance of Ischemic and Bleeding...
solaci -
Coronary disease

Drug Eluting Stents: Does Strut Size Matter?

The benefit of first-generation Drug-Eluting Stents (DES) over Bare Metal Stents (BMS) is largely known. Moreover, technological...
solaci -
Acute coronary syndromes

Is Coronary Revascularization Useful in Renal Transplant Candidates?

Coronary artery disease is the main cause of death in patients with functioning renal transplant, reaching 30%,...
solaci -
Acute coronary syndromes

Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in...
solaci -